CoChat
Sign Up
Cited by 271Chronic Kidney Disease and DiabetesStatistical Methods in Clinical TrialsEthics in Clinical Research

The DOI matches its Crossref record; 116 of the 117 references it cites were found in a registry or an index.

The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease

Open access
Charytan, D., Kuntz, R.E.·2006·Kidney International
DOI 10.1038/sj.ki.5001934PMC PMC2950017
Open this paper in CoChat — free account

Abstract

Chronic kidney disease (CKD) is associated with a high risk of death from coronary artery disease and may modify the response to standard cardiovascular therapies. Treatment of subjects with CKD should ideally be based on evidence from randomized, clinical trials, but how often subjects with CKD have been excluded from these trials is uncertain. We undertook this study in order to quantify how often subjects with moderate to advanced CKD were excluded from large cardiovascular trials. MEDLINE and the reference list of selected articles were searched in order to identify large, randomized, controlled trials of five different coronary artery disease therapies published between 1998 and 2005. Exclusion criteria and reported clinical characteristics of subjects were abstracted. Rates of exclusion and reporting of baseline characteristics of study participants were compared for CKD, diabetes, history of smoking, and hypertension. Eighty-six trials randomizing 411 653 patients were identified. More than 80% of trials excluded subjects with end-stage renal disease and 75.0% excluded patients with CKD. Subjects with diabetes, hypertension, or a history of smoking were excluded less than 4% of the time. Baseline renal function of study participant was reported in only 7% of trials. Patients with CKD are frequently excluded from coronary artery disease trials and renal function of randomized subjects is rarely reported. These findings reinforce the notion that available data on the tre…

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.ki.5001934

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 117 references

1 of the 117 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Gilbertson, 2003, Projecting the US ESRD population to 2030, J Am Soc Nephrol, 14, F-PO881

Cited by

Sorted by citations

Items 101–200 of 271

Related

See all

Metadata

Authors
Charytan, D., & Kuntz, R. E.
Affiliations
  • Brigham and Women's Hospital (US)
  • Medtronic (United States) (US)
Corresponding author
Charytan, D.
ORCID
Charytan, D.
Venue
Kidney International
Publisher
Elsevier BV
Published
2006-12
Volume
70
Issue
11
Pages
2021-2030
ISSN
0085-2538 (ISSN-L)
DOI
10.1038/sj.ki.5001934
PMC
PMC2950017
OpenAlex
W2030060276
Cited by
271
References
117
Citations by year
2026: 7 · 2025: 10 · 2024: 24 · 2023: 19 · 2022: 17 · 2021: 24 · 2020: 24 · 2019: 13 · 2018: 17 · 2017: 18 · 2016: 11 · 2015: 9 · 2014: 14 · 2013: 10 · 2012: 11
FWCI
5.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Kidney International (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institutes of Health (T32 DK007527-22)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
Keywords
chronic kidney disease, coronary artery disease, exclusion criteria, inclusion and exclusion criteria, end-stage renal disease, diabetes mellitus, hypertension, smoking history, cardiovascular disease treatment, generalizability of trial results
MeSH terms
Adrenergic beta-Antagonists, Clinical Trials as Topic, Coronary Artery Disease, Humans, Platelet Aggregation Inhibitors, Patient Selection, Platelet Glycoprotein GPIIb-IIIa Complex, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review